Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients

Inclusion Criteria:

1. Age of 18-55 years;
2. Patients that meet the diagnostic criteria of acute myeloid leukemia (except M3 and M7 subtypes), and achieve complete remission following induction chemotherapy and undergo consolidation therapy;
3. Patients who require two successive cycles of DA (Ara-c 1.5 g/m2/q12 h and DNR 40 mg/m2/d on days 1-3) or MA regimen (Ara-C 1.5 g/m2/q12 h and MTZ 6 mg/m2/d on days 1-3) at the phase of consolidation therapy, or underwent consolidation therapy with administration of Ara-C 3 g/m2/q12 h alone, with dose adjustment of less than 10% Ara-C dose;
4. Patients with the minimum platelet count of \< 30´109/L at the final cycle of chemotherapy during the induction stage;
5. Patients without apparent liver or renal dysfunctions (serum levels of urea nitrogen, creatinine, aminotransferase and bilirubin were all ≤ 1.5 times of the normal upper limit);
6. Patients without severe heart or lung dysfunctions;
7. Patients with life expectancy of \> 12 weeks;
8. Patients with ECOG score of ≤ 2;
9. Patients are willing to participate in the study and sign the informed consent.

Exclusion Criteria:

1. Patients with a medical history of severe allergy to biologics;
2. Patients with thromboembolic or hemorrhagic disease, or a recent medical history of thrombosis;
3. Patients with a history of mental disorders;
4. Pregnant or lactating patients, or patients with failure in use of contraception during the study period;
5. Patients with M3 or M7 subtype;
6. Patients with a platelet count of 1000 ´109/L at the start of the study;
7. Patients with other factors which were considered not to be suitable to participate in the study by the investigators.